Detail Cantuman

a b s t r a c t
Background: The most common childhood malignancy is B-cell precursor acute leukemia
(BCP-ALL). Leukemic cells remaining in the patient's bone marrow during treatment
are the major cause of relapse; therefore, minimal residual disease monitoring (MRD)
during the induction therapy is predicting factor of treatment outcome. Multicolor
flow
cytometry (MFC) is the commonly used technique during follow-up of leukemia in bone
marrow. Materials and methods: MRD was assessed by MFC in 44 patients with BCP-ALL
from the Oncology and Hematology Department, Children's University Hospitalin Krakow
diagnosed between 2011 and 2013. The level of residual leukemic cells and the quality of
antigen expression was assessed on leukemic cell on diagnosis day and 15th day of
induction chemotherapy. Six-color panel of monoclonal antibodies was used. To achieve
expected sensitivity of the method (10-4), at least 300.000 nucleated cells were collected.
Results: CD10 expression was changed in residual leukemic cells of most patients on day
15 of treatment, in comparison to day 0. The most significant decrease of CD10 expres-
sion occurs in standard risk group. CD10 level is correlated with the level of blasts in day
15, which is the most significant in high-risk group. The patients, in whom the level of
CD10 expression increases during treatment, were statistically significantly associated
with worse response to therapy. Conclusions: The immunophenotypic shifts at day 15
were observed in most patients. Not only are the quantitative MRD results important,
but also qualitative changes of immunophenotype of residual leukemic cells might bring
additional clinical information.
© 2017 Polskie Towarzystwo Hematologów i Transfuzjologów, Instytut Hematologii i
Transfuzjologii. Published by Elsevier Sp. z o.o. All rights reserved